Dung Hoang1, Yanxun Xu2, Olivia Lutz1, Deepthi Bannai1, Victor Zeng1, Jeffrey R Bishop3, Matcheri Keshavan4, Paulo Lizano5. 1. Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, USA. 2. Department of Applied Mathematics and Statistics, Johns Hopkins University, Baltimore, MD, USA. 3. Department of Experimental and Clinical Pharmacology and Psychiatry, University of Minnesota, Minneapolis, MN, USA. 4. Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, USA; Department of Psychiatry, Harvard Medical School, Boston, MA, USA. 5. Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, USA; Department of Psychiatry, Harvard Medical School, Boston, MA, USA. Electronic address: lizanopl@gmail.com.
Abstract
BACKGROUND: Peripheral inflammation is implicated in schizophrenia, however, not all individuals demonstrate inflammatory alterations. Recent studies identified inflammatory subtypes in chronic psychosis with high inflammation having worse cognitive performance and displaying neuroanatomical enlargement compared to low inflammation subtypes. It is unclear if inflammatory subtypes exist earlier in the disease course, thus, we aim to identify inflammatory subtypes in antipsychotic naïve First-Episode Schizophrenia (FES). METHODS: 12 peripheral inflammatory markers, clinical, cognitive, and neuroanatomical measures were collected from a naturalistic study of antipsychotic-naïve FES patients. A combination of unsupervised principal component analysis and hierarchical clustering was used to categorize inflammatory subtypes from their cytokine data (17 FES High, 30 FES Low, and 33 healthy controls (HCs)). Linear regression analysis was used to assess subtype differences. Neuroanatomical correlations with clinical and cognitive measures were performed using partial Spearman correlations. Graph theoretical analyses were performed to assess global and local network properties across inflammatory subtypes. RESULTS: The FES High group made up 36% of the FES group and demonstrated significantly greater levels of IL1β, IL6, IL8, and TNFα compared to FES Low, and higher levels of IL1β and IL8 compared to HCs. FES High had greater right parahippocampal, caudal anterior cingulate, and bank superior sulcus thicknesses compared to FES Low. Compared to HCs, FES Low showed smaller bilateral amygdala volumes and widespread cortical thickness. FES High and FES Low groups demonstrated less efficient topological organization compared to HCs. Individual cytokines and/or inflammatory signatures were positively associated with cognition and symptom measures. CONCLUSIONS: Inflammatory subtypes are present in antipsychotic-naïve FES and are associated with inflammation-mediated cortical expansion. These findings support our previous findings in chronic psychosis and point towards a connection between inflammation and blood-brain barrier disruption. Thus, identifying inflammatory subtypes may provide a novel therapeutic avenue for biomarker-guided treatment involving anti-inflammatory medications.
BACKGROUND: Peripheral inflammation is implicated in schizophrenia, however, not all individuals demonstrate inflammatory alterations. Recent studies identified inflammatory subtypes in chronic psychosis with high inflammation having worse cognitive performance and displaying neuroanatomical enlargement compared to low inflammation subtypes. It is unclear if inflammatory subtypes exist earlier in the disease course, thus, we aim to identify inflammatory subtypes in antipsychotic naïve First-Episode Schizophrenia (FES). METHODS: 12 peripheral inflammatory markers, clinical, cognitive, and neuroanatomical measures were collected from a naturalistic study of antipsychotic-naïve FES patients. A combination of unsupervised principal component analysis and hierarchical clustering was used to categorize inflammatory subtypes from their cytokine data (17 FES High, 30 FES Low, and 33 healthy controls (HCs)). Linear regression analysis was used to assess subtype differences. Neuroanatomical correlations with clinical and cognitive measures were performed using partial Spearman correlations. Graph theoretical analyses were performed to assess global and local network properties across inflammatory subtypes. RESULTS: The FES High group made up 36% of the FES group and demonstrated significantly greater levels of IL1β, IL6, IL8, and TNFα compared to FES Low, and higher levels of IL1β and IL8 compared to HCs. FES High had greater right parahippocampal, caudal anterior cingulate, and bank superior sulcus thicknesses compared to FES Low. Compared to HCs, FES Low showed smaller bilateral amygdala volumes and widespread cortical thickness. FES High and FES Low groups demonstrated less efficient topological organization compared to HCs. Individual cytokines and/or inflammatory signatures were positively associated with cognition and symptom measures. CONCLUSIONS: Inflammatory subtypes are present in antipsychotic-naïve FES and are associated with inflammation-mediated cortical expansion. These findings support our previous findings in chronic psychosis and point towards a connection between inflammation and blood-brain barrier disruption. Thus, identifying inflammatory subtypes may provide a novel therapeutic avenue for biomarker-guided treatment involving anti-inflammatory medications.
Authors: Paulo L Lizano; Matcheri S Keshavan; Neeraj Tandon; Ian T Mathew; Suraj Sarvode Mothi; Debra M Montrose; Jeffrey K Yao Journal: Schizophr Res Date: 2015-12-11 Impact factor: 4.939
Authors: Benedicto Crespo-Facorro; Roberto Roiz-Santiáñez; José María Pelayo-Terán; Cesar González-Blanch; Rocío Pérez-Iglesias; Agustín Gutiérrez; Enrique Marco de Lucas; Diana Tordesillas; José Luis Vázquez-Barquero Journal: Schizophr Res Date: 2007-02-15 Impact factor: 4.939
Authors: Tyrone D Cannon; Yoonho Chung; George He; Daqiang Sun; Aron Jacobson; Theo G M van Erp; Sarah McEwen; Jean Addington; Carrie E Bearden; Kristin Cadenhead; Barbara Cornblatt; Daniel H Mathalon; Thomas McGlashan; Diana Perkins; Clark Jeffries; Larry J Seidman; Ming Tsuang; Elaine Walker; Scott W Woods; Robert Heinssen Journal: Biol Psychiatry Date: 2014-06-12 Impact factor: 13.382
Authors: Charles L Raison; Robin E Rutherford; Bobbi J Woolwine; Chen Shuo; Pamela Schettler; Daniel F Drake; Ebrahim Haroon; Andrew H Miller Journal: JAMA Psychiatry Date: 2013-01 Impact factor: 21.596
Authors: Danny Boerrigter; Thomas W Weickert; Rhoshel Lenroot; Maryanne O'Donnell; Cherrie Galletly; Dennis Liu; Martin Burgess; Roxanne Cadiz; Isabella Jacomb; Vibeke S Catts; Stu G Fillman; Cynthia Shannon Weickert Journal: J Neuroinflammation Date: 2017-09-18 Impact factor: 8.322
Authors: Lusi Zhang; Paulo Lizano; Bin Guo; Yanxun Xu; Leah H Rubin; S Kristian Hill; Ney Alliey-Rodriguez; Adam M Lee; Baolin Wu; Sarah K Keedy; Carol A Tamminga; Godfrey D Pearlson; Brett A Clementz; Matcheri S Keshavan; Elliot S Gershon; John A Sweeney; Jeffrey R Bishop Journal: Brain Behav Immun Health Date: 2022-04-08
Authors: Jonah F Byrne; Colm Healy; David Mongan; Subash Raj Susai; Stan Zammit; Melanie Fӧcking; Mary Cannon; David R Cotter Journal: Transl Psychiatry Date: 2022-09-09 Impact factor: 7.989